drugset / Trial / NCT02858804
EDOCH Alternating With DHAP for New Diagnosed Younger MCL
Non-randomizedParallel-groupOpen-labelTreatment
Summary
The purpose of this study is to: 1. determine the efficiency of EDOCH (etoposide,dexamethasone,doxorubicin, cyclophosphamide and vincristine) alternating with DHAP (cisplatin, cytarabine and dexamethasone) regimen combined with rituximab or not in young mantle cell lymphoma patients (age≤65 years); 2. determine the efficiency of rituximab and thalidomide plus prednisone as maintenance regimens.
Timeline
- Start
- 2016-01
- Primary completion
- 2019-12
- Completion
- 2020-06
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Cisplatin | Other / unclassified | 100 mg/m2 | Intravenous |
| Subject | Cyclophosphamide | Other / unclassified | 750 mg/m2 | — |
| Subject | Cytarabine | Small molecule | 2000 mg/m2 | — |
| Subject | Dexamethasone | Small molecule | 30 mg | — |
| Subject | Doxorubicin | Other / unclassified | 10 mg/m2 | Intravenous |
| Subject | Etoposide | Small molecule | 50 mg/m2 | Intravenous |
| Subject | Prednisone | Other / unclassified | 0.5 mg/kg | Oral |
| Subject | Rituximab | Monoclonal antibody | 375 mg/m2 | Intravenous |
| Subject | Thalidomide | Other / unclassified | 50 mg | Oral |
| Subject | Thalidomide | Other / unclassified | 150 mg | Oral |
| Subject | Vincristine | Small molecule | 0.4 mg/m2 | Intravenous |